Immunotherapy; T-cells; immune regulation; clinical trials
Our Focus
The point of focus of my group is the study on host-tumour interactions which determine the success and failure in immune control of solid cancer in order to improve and develop immunotherapeutic strategies. Several types of fundamental, translational and clinical studies are performed with emphasis on Human Papilloma Virus-induced cancers, Ovarian cancer, Melanoma, Lung cancer and Pancreatic cancer. The main basic research questions which are currently being addressed are: 1) immune therapy driven resistance mechanisms; 2) the role of innate immune cells in immunotherapy driven tumor regression; Clinical studies focus on cancer vaccination and adoptive T cell transfer in combination with other treatment modalities such as immunomodulation, chemotherapy, radiotherapy, and checkpoint therapy to enhance the efficacy and specificity of immune responses.
About Sjoerd van der Burg
Sjoerd van der Burg
Key Publications
Z. Abdulrahman, S.J. Santegoets, G. Sturm, P. Charoentong, M.E. IJsselsteijn, A. Somarakis, T. Höllt, F. Finotello, Z. Trajanoski, S.L. van Egmond, D.A.M. Mustafa, M.J.P. Welters, N.F.C.C. de Miranda,S.H. van der Burg (2022) Chemokine-driven spatial organization of immune cell microaggregates marks oropharyngeal squamous cell carcinomas containing tumor-specific T cells. J. Immunother. Cancer, e004346
C.L. Duurland, S.J. Santegoets, Z. Abdulrahman, N.M. Loof, G. Sturm, T.H. Wesselink, R. Arens, S. Boekestijn, I. Ehsan, M.I.E. van Poelgeest, F. Finotello, H. Hackl, Z. Trajanoski, P. ten Dijke, V.M. Braud, M.J.P. Welters, S.H. van der Burg(2022) CD161 expression and regulation defines rapidly responding effector CD4+ T cells associated with improved survival in HPV16-associated tumors. J. Immunother. Cancer, 10:e003995
K.E. Kortekaas, S.J. Santegoets, L. Tas, I. Ehsan, P. Charoentong, H.C. van Doorn, M.I.E. van Poelgeest, D.A.M. Mustafa, S.H. van der Burg (2021) Primary vulvar squamous cell carcinomas with high T cell infiltration and active immune signaling are potential candidates for neoadjuvant PD1/PD-L1 immunotherapy. J. Immunother. Cancer, 9:e003671
E. Beyranvand Nejad, C. Labrie, M.J. van Elsas, J.W. Kleinovink, H.W. Mittrücker, K.L.M.C. Franken, S. Heink, T. Korn, R. Arens, T. van Hall, S.H. van der Burg (2021) IL-6 signalling in macrophages is required for immunotherapy-driven regression of tumors. J. Immunother. Cancer, 9:e002460
M. Saxena*, S.H. van der Burg*, C.J.M. Melief*, N. Bhardwaj* (2021) Therapeutic cancer vaccines. Nat Rev Cancer, 21:360-378
E. Beyranvand Nejad, C. Labrie, Z. Abdulrahman, M.J. van Elsas, E. Rademaker, J.W. Kleinovink, T.C. van der Sluis, S. van Duikeren, A.F.A.S. Teunisse, A.G. Jochemsen, J. Oosting, N.F.C.C de Miranda, T. van Hall, R. Arens, S.H. van der Burg (2020) Lack of myeloid cell infiltration as an acquired resistance strategy to immunotherapy. J. Immunother. Cancer, 8: e001326
S.J. Santegoets, C.L. Duurland, E.S. Jordanova, J.J. van Ham, I. Ehsan, N.M. Loof, V. Narang, C.A. Dutertre, F. Ginhoux, S.L. van Egmond, M.J.P. Welters, S.H. van der Burg (2020)CD163+ cytokine-producing cDC2 stimulate intratumoral type 1 T cell responses in HPV16-induced oropharyngeal cancer. J. Immunother. Cancer, 8:e001053
K.E. Kortekaas, S.J. Santegoets, G. Sturm, I. Ehsan, S.I. van Egmond, F. Finotello, Z. Trajanoski, M.J.P. Welters, M.I.E. van Poelgeest, S.H. van der Burg (2020) CD39 identifies the CD4-positive tumor-specific T cell population in human cancer. Cancer Immunol. Res., 8: 1311-1321
E.M.E. Verdegaal*, M.K. van der Kooij*, M. Visser, C.E. van der Minne, L. de Bruin, P.M. Meij, A.G.T. Terwisscha van Scheltinga, M.J.P. Welters, S.J.A.M. Santegoets, N.F.C.C. de Miranda C.F.M. Roozen, G.J. Liefers, E. Kapiteijn**, S.H. van der Burg** (2020) Low-dose Interferon-alpha pre-conditioning and adoptive cell therapy in metastatic melanoma patients refractory to standard (immune) therapies – a phase 1/2 study. J. Immunother. Cancer, 8: e000166
C.J.M. Melief*, M.J.P. Welters*, I. Vergote, J.R. Kroep, G.G. Kenter, P.B. Ottevanger, W.A.A. Tjalma, H. Denys, M.I.E. van Poelgeest, H.W. Nijman, A.K.L. Reyners, T. Velu, F. Goffin, R.I. Lalisang, N.M. Loof, S. Boekestijn, W.J. Krebber, L. Hooftman, S.Visscher, B.A. Blumenstein, R.B. Stead, W. Gerritsen**, S.H. van der Burg** (2020) Strong vaccine responses during chemotherapy are associated with prolonged cancer survival. Science Translational Medicine, 12 (535): eaaz8235
Z. Abdulrahman, N.F.C.C. de Miranda, E.M.G. van Esch, P.J. de Vos van Steenwijk, H.W. Nijman, M.J.P. Welters, M.I.E. van Poelgeest*, S.H. van der Burg* (2020) Pre-existing inflammatory immune microenvironment predicts the clinical response of vulvar high-grade squamous intraepithelial lesions to therapeutic HPV16 vaccination. J. Immunother. Cancer, 8(1): e000653
N. Hilf, S. Kuttruff-Coqui, K. Frenzel, V. Bukur, S. Stevanovic, C. Gouttefangeas, M. Platten, G. Tabatabai, V. Dutoit, S.H. van der Burg, P. thor Straten, F. Martinez Ricarte, B. Ponsati, H. Okada, U. Lassen, A. Admon, C.H. Ottensmeier, A. Ulges, S. Kreiter, A. von Deimling, M. Skardelly, D. Migliorini, J.R. Kroep, M. Idorn, J. Rodon, J. Piro, H.S. Poulsen, B. Shraibman, K. McCann, R. Mendrzyk, M. Löwer, M. Stieglbauer, C. Britten, D. Capper, M.J.P. Welters, J. Sahuquillo, K. Kiesel, E. Derhovanessian, E. Rusch, C. Song, S. Heesch, C. Wagner, A. Kemmer-Brueck, J. Ludwig, J.C. Castle, O. Schoor, A. Tadmor, J. Fritsche, M. Meyer, N. Pawlowski, S. Dorner, F. Hoffgaard, B. Rössler, D. Maurer, T. Weinschenk, C. Reinhardt, C. Huber, H.G. Rammensee, H. Singh, U. Sahin, P.Y. Dietrich, W. Wick (2019) Actively personalized vaccination in newly diagnosed glioblastoma. Nature, 565:240-245
E.M.E. Verdegaal, N.F. de Miranda, M. Visser, T. Harryvan, M.M. van Buuren, R.S. Andersen, S.R. Hadrup, C.E. van der Minne, R. Schotte, H. Spits, J.B.A.G. Haanen, E.H.W. Kapiteijn, T.N. Schumacher, S.H. van der Burg (2016) Neoantigen landscape dynamics during human melanoma-T cell interactions. Nature, 526:91-95
M.J. Welters*, T.C. van der Sluis*, H. van Meir*, N.M. Loof, H.J. van Ham, S. van Duikeren, S.J. Santegoets, R. Arens, M.L. de Kam, A.F. Cohen, M.I.E. van Poelgeest, G.G. Kenter, J.R. Kroep, K. Burggraaf, C.J.M. Melief, S.H. van der Burg (2016) Vaccination during myeloid cell depletion by cancer chemotherapy fosters robust T-cell responses. Science Translational Med., 8:334ra52
C. Linnemann, M.M. van Buuren, L. Bies, E.M. Verdegaal, R. Schotte, J.J.A. Calis, S. Behjati, A. Velds, H. Hilkmann, D. el Atmioui, M. Visser, M.R. Stratton, J.B.A.G. Haanen, H. Spits, S.H. van der Burgand T.N.M. Schumacher (2015) Intratumoral CD4+ T cell reactivity against mutated antigens is commonly observed in human melanoma. Nature Med., 21:81-85
Members
| Sjoerd van der Burg Group leader | Anique Verpoorte | Anneloes van Duijn Phd Candidate |
| Kim Kortekaas PhD student | Camilla Labrie Technician | Els Verdegaal Assistant Professor |
| Gaby Schaap Analyst | Hester Heimans Phd candidate | Maarten Nijen Twilhaar |
| Lien van der Minne Lab Manager | Linda de Bruin Technician | Lisa Griffioen |
Marij Welters | Marjolein Sluijter | Tetje C van der Sluis Postdoc |
| Paula Ruibal Project Manager | Pieter Schol Phd student | Roderick Slieker PhD student |
| Sanne Boekestijn Technician | Saskia Santegoets Postdoc | Thorbald van Hall Assistant Professor |
Tsolere Arakelian | Vera Weeda Technician | Ziena Abdulrahman Arts-onderzoeker |
| Nynke Damstra Technician |